Amenamevir Transfer into Breast Milk in Patients with Herpes Simplex Virus Infection: A Brief Report of a Prospective Multicenter Study
The Journal of Dermatology · 2026-11 · 53 (11) · 1682-1685
DOI: 10.1111/1346-8138.70474 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Dermatology, online erschienen am 31.08.2026. Verfasst von Sachi Koinuma und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Japan Drug Information Institute in Pregnancy, Integrated Center for Women's Health, National Center for Child Health and Development, Tokyo, Jap…. Hauptthemen laut MEDLINE: Milk, Human, Antiviral Agents, Oxadiazoles, Herpes Simplex. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Maruho Co. Ltd..
Abstract (Originalsprache)
Patient–initiated therapy (PIT) is a treatment approach in which patients with recurrent herpes simplex self–administer medication at the onset of prodromal symptoms. PIT, which allows patients to receive medication in advance and initiate treatment at any time, is a therapeutic approach that alleviates the burden of urgent clinic visits for acute diseases like herpes simplex and benefits many people. Furthermore, its utility is particularly high for breastfeeding women for whom clinic visits can sometimes be difficult. When PIT is used in breastfeeding patients, potential drug transfer into breast milk and infant exposure must be considered. However, no studies have evaluated the extent of amenamevir transfer into human breast milk or its safety in infants. In this study, the relative infant dose (RID) was estimated from breast milk concentrations after a single oral dose of amenamevir. In the two cases evaluated, the estimated RID values were below 1%. This preliminary data suggest low estimated transfer of amenamevir into human milk after PIT. However, because breastfeeding was interrupted and infant exposure was not evaluated, clinical safety in breastfed infants remains undetermined. Trial Registration: Japan Registry of Clinical Trials identifier: jRCTs031230591
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Japan Drug Information Institute in Pregnancy, Integrated Center for Women's Health, National Center for Child Health and Development, Tokyo, Japan.
- Department of Pharmacy, National Center for Child Health and Development, Tokyo, Japan.
- Aoki Obstetrics and Gynecology Clinic, Tokyo, Japan.
- Tokyo Mother's Clinic, Tokyo, Japan.
- Medical Affairs Department, Maruho Co. Ltd., Osaka, Japan.
ORCID-Profile: Sachi Koinuma, Mikako Goto, Jumpei Saito, Hiroaki Aoki
Förderung
- Maruho Co. Ltd.
Zitieren
APA
Koinuma, S., Goto, M., Saito, J., Aoki, H., Hayashi, S., & Takeshita, T. (2026). Amenamevir Transfer into Breast Milk in Patients with Herpes Simplex Virus Infection: A Brief Report of a Prospective Multicenter Study. The Journal of Dermatology, 53(11), 1682-1685. https://doi.org/10.1111/1346-8138.70474
Vancouver
Koinuma S, Goto M, Saito J, Aoki H, Hayashi S, Takeshita T. Amenamevir Transfer into Breast Milk in Patients with Herpes Simplex Virus Infection: A Brief Report of a Prospective Multicenter Study. The Journal of Dermatology. 2026;53(11):1682-1685. doi:10.1111/1346-8138.70474
BibTeX
@article{Koinuma2026,
author = {Koinuma, Sachi and Goto, Mikako and Saito, Jumpei and Aoki, Hiroaki and Hayashi, Satoshi and Takeshita, Tomoyoshi},
title = {Amenamevir Transfer into Breast Milk in Patients with Herpes Simplex Virus Infection: A Brief Report of a Prospective Multicenter Study},
journal = {The Journal of Dermatology},
year = {2026},
volume = {53},
number = {11},
pages = {1682--1685},
doi = {10.1111/1346-8138.70474}
}
EUVIMED